App-Quantinova.ai

Olaparib combined with abiraterone in patients with metastatic prostate cancer: Safety run-in from a phase II study.

Noel W. Clarke - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): Effect of early docetaxel on outcomes.

Benjamin Louis Maughan - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.

Christopher Sweeney - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Edwin M. Posadas - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).

Charles J. Ryan - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment-ABIDO-SOGUG Trial.

Ignacio Duran - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients.

Edith Carton - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Metastatic castration-resistant prostate cancer

CB-7598

Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Ravinder Dhawan - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).

Vincenza Conteduca - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

What predicts minimal response to abiraterone in metastatic castrate resistant prostate cancer?

Rhian Sian Davies - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study-GETHI 2013-01.

Jf. Rodriguez-Moreno - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

CB-7598

ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-nave metastatic castration-resistant prostate cancer (mCRPC).

Gerhardt Attard - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

Dana E. Rathkopf - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.

Kim N. Chi - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D).

Robert B. Montgomery - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P).

Fred Saad - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Eric Jay Small - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results.

Christophe Massard - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).

Diletta Bianchini - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).

Raya Leibowitz-Amit - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Filters

959 Abstracts